Vaccination for the novel coronavirus disease in hematological disorders
Open Access
- 14 September 2021
- journal article
- Published by Scientific Scholar in Journal of Hematology and Allied Sciences
- Vol. 1, 59-68
- https://doi.org/10.25259/jhas_18_2021
Abstract
The coronavirus disease-19 (COVID-19) caused by the SARS-CoV-2 virus, is now an ongoing pandemic. First detected in December 2019 at Wuhan, China, this disease has now spread to all parts of the world. COVID-19 may affect anyone, without regard for age, sex, or underlying disease condition. Patients with benign or malignant diseases when affected, usually have a more severe outcome than people without comorbidities. Increasing one’s immunity by vaccination against COVID-19 will help to improve the disease outcomes of COVID-19 in patients who already have some underlying disease. The live-attenuated or killed and recombinant viral protein vaccines currently available can elicit both humoral and cellular immunities. However, in immunocompromised patients (either due to the disease pathology or treatment-related immunosuppression), immune response may not be as effective as expected. Depending on the underlying disease pathogenesis, the patient may not be able to mount an adequate immune response post-vaccination. However, in view of the severe risks posed by COVID-19 disease, vaccination is of utmost importance. This review aims at understanding the importance of SARS-CoV-2 vaccination in patients with hematological disorders, and also aims to understand the side effects which arise post-SARS-CoV-2 vaccination. We have tried to ascertain the best way to vaccinate patients with hematological disorders.Keywords
This publication has 33 references indexed in Scilit:
- Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy PatientInfectious Disease Clinics of North America, 2019
- Ibrutinib may impair serological responses to influenza vaccinationHaematologica, 2017
- Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccineSeminars in Hematology, 2016
- 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised HostClinical Infectious Diseases, 2013
- The effect of rituximab on vaccine responses in patients with immune thrombocytopeniaBlood, 2013
- Influenza vaccination can induce new-onset anticardiolipins but not β2-glycoprotein-I antibodies among patients with systemic lupus erythematosusLupus, 2012
- Immunological mechanisms of vaccinationNature Immunology, 2011
- Burden of Influenza-Related Hospitalizations Among Children With Sickle Cell DiseasePEDIATRICS, 2010
- Randomized Study of Early versus Late Immunization with Pneumococcal Conjugate Vaccine after Allogeneic Stem Cell TransplantationClinical Infectious Diseases, 2009
- ORIGINAL ARTICLE: Murine Monoclonal Antibody 26 Raised Against Tetanus Toxoid Cross‐Reacts with β2‐Glycoprotein I: Its Characteristics and Role in Molecular MimicryAmerican Journal of Reproductive Immunology, 2008